Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance) Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Meta-Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance) Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017 Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104
Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Long-Term-Followup - Myeloma - CALGB-100104
Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma Holstein, Sarah A. , Suman, Vera J. , Owzar, Kouros , Santo, Katelyn ... - - Biol. Blood Marrow Transplant. - 2020 Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100001
CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO) McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance) McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017 Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance) McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Voorhees, Peter M , Kaufman, Jonathan L , Laubach, Jacob ... - - Blood - 2020 Manuscript - Primary - Primary - Myeloma - AFT-29